Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:belinostat
go back to main search page
Accession:CHEBI:61076 term browser browse the term
Definition:A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
Synonyms:exact_synonym: (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
 related_synonym: (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide;   Formula=C15H14N2O4S;   InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+;   InChIKey=NCNRHFGMJRPRSK-MDZDMXLPSA-N;   N-Hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide;   PXD101;   SMILES=ONC(=O)\\C=C\\c1cccc(c1)S(=O)(=O)Nc1ccccc1
 xref: CAS:414864-00-9;   KEGG:D08870
 xref_mesh: MESH:C487081
 xref: PMID:23382909;   PMID:23475695;   PMID:23644904;   PMID:24020452;   PMID:24369094;   PMID:24800886;   PMID:24918834;   PMID:25134672;   PMID:25189481;   PMID:25368524;   PMID:25389633;   PMID:25404094;   PMID:25433307;   PMID:25446119;   PMID:25483416;   PMID:25611313;   PMID:25673888;   Reaxys:10087570;   Wikipedia:Belinostat


show annotations for term's descendants           Sort by:
 
belinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc6 ATP binding cassette subfamily C member 6 decreases expression ISO belinostat results in decreased expression of ABCC6 mRNA CTD PMID:27188386 NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases expression ISO belinostat results in decreased expression of ABL1 mRNA CTD PMID:19606018 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Acacb acetyl-CoA carboxylase beta decreases expression ISO belinostat results in decreased expression of ACACB mRNA CTD PMID:27188386 NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
JBrowse link
G Acadsb acyl-CoA dehydrogenase, short/branched chain increases expression ISO belinostat results in increased expression of ACADSB mRNA CTD PMID:26272509 NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression ISO belinostat results in increased expression of ACKR3 mRNA CTD PMID:27188386 NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant decreases expression ISO belinostat results in decreased expression of ACP5 mRNA CTD PMID:27188386 NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
JBrowse link
G Acsl5 acyl-CoA synthetase long-chain family member 5 decreases expression ISO belinostat results in decreased expression of ACSL5 mRNA CTD PMID:27188386 NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA CTD PMID:27188386 NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
JBrowse link
G Ada adenosine deaminase decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA CTD PMID:27188386 NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
JBrowse link
G Adamts3 ADAM metallopeptidase with thrombospondin type 1, motif 3 decreases expression ISO belinostat results in decreased expression of ADAMTS3 mRNA CTD PMID:27188386 NCBI chr14:18,231,051...18,437,773
Ensembl chr14:18,231,165...18,435,556
JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
belinostat results in decreased expression of ADGRG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860
JBrowse link
G Adi1 acireductone dioxygenase 1 decreases expression ISO belinostat results in decreased expression of ADI1 mRNA CTD PMID:27188386 NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
JBrowse link
G Afp alpha-fetoprotein decreases expression ISO belinostat results in decreased expression of AFP mRNA CTD PMID:26272509 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Ak7 adenylate kinase 7 increases expression ISO belinostat results in increased expression of AK7 mRNA CTD PMID:27188386 NCBI chr 6:124,611,789...124,679,978
Ensembl chr 6:124,611,902...124,679,961
JBrowse link
G Akna AT-hook transcription factor decreases expression ISO belinostat results in decreased expression of AKNA mRNA CTD PMID:27188386 NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO belinostat results in increased phosphorylation of AKT1 protein CTD PMID:23671600 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aldob aldolase, fructose-bisphosphate B decreases expression ISO belinostat results in decreased expression of ALDOB mRNA CTD PMID:27188386 NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
JBrowse link
G Ampd3 adenosine monophosphate deaminase 3 decreases expression ISO belinostat results in decreased expression of AMPD3 mRNA CTD PMID:27188386 NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
JBrowse link
G Angpt1 angiopoietin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ANGPT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
JBrowse link
G Angpt2 angiopoietin 2 decreases expression ISO belinostat results in decreased expression of ANGPT2 mRNA CTD PMID:27188386 NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA CTD PMID:27188386 NCBI chr 7:24,313,810...25,479,307
Ensembl chr 7:24,312,843...25,477,693
JBrowse link
G Ano3 anoctamin 3 increases expression
multiple interactions
ISO belinostat results in increased expression of ANO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions
ISO belinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
JBrowse link
G Anxa4 annexin A4 decreases expression ISO belinostat results in decreased expression of ANXA4 mRNA CTD PMID:27188386 NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression ISO belinostat results in decreased expression of AOX1 mRNA CTD PMID:27188386 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
JBrowse link
G Ap5m1 adaptor related protein complex 5 subunit mu 1 increases expression ISO belinostat results in increased expression of AP5M1 mRNA CTD PMID:26272509 NCBI chr15:22,355,478...22,385,222
Ensembl chr15:22,355,500...22,377,750
JBrowse link
G Apela apelin receptor early endogenous ligand increases expression ISO belinostat results in increased expression of APELA mRNA CTD PMID:26272509 NCBI chr16:24,694,231...24,703,466 JBrowse link
G Apoc1 apolipoprotein C1 decreases expression ISO belinostat results in decreased expression of APOC1 mRNA CTD PMID:27188386 NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
JBrowse link
G Arap3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 decreases expression ISO belinostat results in decreased expression of ARAP3 mRNA CTD PMID:27188386 NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 increases expression
multiple interactions
ISO belinostat results in increased expression of ARHGAP24 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
JBrowse link
G Arhgef37 Rho guanine nucleotide exchange factor 37 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ARHGEF37 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669
JBrowse link
G Arhgef4 Rho guanine nucleotide exchange factor 4 decreases expression ISO belinostat results in decreased expression of ARHGEF4 mRNA CTD PMID:27188386 NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075
JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA CTD PMID:27188386 NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
JBrowse link
G Asgr1 asialoglycoprotein receptor 1 decreases expression ISO belinostat results in decreased expression of ASGR1 mRNA CTD PMID:27188386 NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) decreases expression ISO belinostat results in decreased expression of ASNS mRNA CTD PMID:27188386 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Astn1 astrotactin 1 decreases expression ISO belinostat results in decreased expression of ASTN1 mRNA CTD PMID:26272509 NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 increases expression
multiple interactions
ISO belinostat results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
JBrowse link
G Aurka aurora kinase A decreases expression
decreases activity
ISO belinostat results in decreased expression of AURKA mRNA; belinostat results in decreased expression of AURKA protein
belinostat results in decreased activity of AURKA protein
CTD PMID:19606018 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
JBrowse link
G Aurkb aurora kinase B decreases activity
decreases expression
ISO belinostat results in decreased activity of AURKB protein
belinostat results in decreased expression of AURKB mRNA; belinostat results in decreased expression of AURKB protein
CTD PMID:19606018 NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
JBrowse link
G Aven apoptosis and caspase activation inhibitor decreases expression ISO belinostat results in decreased expression of AVEN mRNA CTD PMID:27188386 NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634
JBrowse link
G B3galnt1 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) decreases expression ISO belinostat results in decreased expression of B3GALNT1 mRNA CTD PMID:27188386 NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332
JBrowse link
G B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 decreases expression
multiple interactions
ISO belinostat results in decreased expression of B3GNT5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166
JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
belinostat results in increased expression of BAG2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
JBrowse link
G Bambi BMP and activin membrane-bound inhibitor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA CTD PMID:27188386 NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
JBrowse link
G Bbs9 Bardet-Biedl syndrome 9 increases expression
multiple interactions
ISO belinostat results in increased expression of BBS9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:21,013,944...21,437,930
JBrowse link
G Bcl11a BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions
ISO belinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO belinostat results in decreased expression of BCL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l11 BCL2 like 11 increases expression ISO belinostat results in increased expression of BCL2L11 protein CTD PMID:18223231 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bfsp1 beaded filament structural protein 1 decreases expression ISO belinostat results in decreased expression of BFSP1 mRNA CTD PMID:27188386 NCBI chr 3:131,195,087...131,252,668
Ensembl chr 3:131,195,087...131,229,337
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO belinostat results in decreased expression of BIRC5 mRNA CTD PMID:19606018 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
belinostat results in increased expression of BMP5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
JBrowse link
G Bmper BMP-binding endothelial regulator increases expression
multiple interactions
ISO belinostat results in increased expression of BMPER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B decreases expression ISO belinostat results in decreased expression of BMPR1B mRNA CTD PMID:26272509 NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
JBrowse link
G Bnc2 basonuclin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
belinostat results in increased expression of BNC2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:98,679,071...99,079,742
Ensembl chr 5:98,687,410...99,079,426
JBrowse link
G Borcs8 BLOC-1 related complex subunit 8 increases expression
multiple interactions
ISO belinostat results in increased expression of BORCS8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:19,274,305...19,280,969
Ensembl chr16:19,274,023...19,280,339
JBrowse link
G Bspry B-box and SPRY domain containing multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA CTD PMID:27188386 NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression ISO belinostat results in decreased expression of CA4 mRNA CTD PMID:27188386 NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
JBrowse link
G Cables1 Cdk5 and Abl enzyme substrate 1 decreases expression ISO belinostat results in decreased expression of CABLES1 mRNA CTD PMID:27188386 NCBI chr18:3,076,556...3,181,183
Ensembl chr18:3,075,524...3,181,181
JBrowse link
G Cad carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase decreases expression ISO belinostat results in decreased expression of CAD mRNA CTD PMID:19606018 NCBI chr 6:25,292,133...25,315,176
Ensembl chr 6:25,292,133...25,319,861
JBrowse link
G Calb1 calbindin 1 increases expression ISO belinostat results in increased expression of CALB1 mRNA CTD PMID:26272509 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
JBrowse link
G Calhm6 calcium homeostasis modulator family member 6 decreases expression ISO belinostat results in decreased expression of CALHM6 mRNA CTD PMID:27188386 NCBI chr20:26,095,591...26,097,336
Ensembl chr20:26,095,592...26,097,278
JBrowse link
G Calml4 calmodulin-like 4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CALML4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:63,323,351...63,335,234
JBrowse link
G Caprin1 cell cycle associated protein 1 decreases expression ISO belinostat results in decreased expression of CAPRIN1 mRNA CTD PMID:27188386 NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
JBrowse link
G Card10 caspase recruitment domain family, member 10 decreases expression ISO belinostat results in decreased expression of CARD10 mRNA CTD PMID:27188386 NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein] CTD PMID:18223231 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 increases expression
multiple interactions
ISO belinostat results in increased expression of CASP8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 increases cleavage
multiple interactions
ISO belinostat results in increased cleavage of CASP9 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]
CTD PMID:18223231 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Ccdc34 coiled-coil domain containing 34 increases expression ISO belinostat results in increased expression of CCDC34 mRNA CTD PMID:27188386 NCBI chr 3:96,552,992...96,588,303
Ensembl chr 3:96,552,992...96,588,146
JBrowse link
G Ccdc69 coiled-coil domain containing 69 increases expression
multiple interactions
ISO belinostat results in increased expression of CCDC69 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,173,282...39,199,878
JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions
ISO belinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression
multiple interactions
ISO belinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
JBrowse link
G Ccn1 cellular communication network factor 1 increases expression ISO belinostat results in increased expression of CCN1 mRNA CTD PMID:23671600 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
JBrowse link
G Ccn2 cellular communication network factor 2 increases expression ISO belinostat results in increased expression of CCN2 mRNA CTD PMID:19606018 PMID:23671600 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO belinostat results in decreased expression of CCNA2 mRNA CTD PMID:19606018 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO belinostat results in decreased expression of CCNB1 mRNA CTD PMID:19606018 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd2 cyclin D2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CCND2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Cd24 CD24 molecule multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
belinostat results in increased expression of CD24 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
JBrowse link
G Cd9 CD9 molecule increases expression
multiple interactions
ISO belinostat results in increased expression of CD9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
JBrowse link
G Cdc25b cell division cycle 25B decreases expression ISO belinostat results in decreased expression of CDC25B mRNA CTD PMID:19606018 NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
JBrowse link
G Cdc25c cell division cycle 25C decreases expression ISO belinostat results in decreased expression of CDC25C mRNA CTD PMID:29733868 NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CDH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Cdh18 cadherin 18 increases expression ISO belinostat results in increased expression of CDH18 mRNA CTD PMID:26272509 NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:73,345,005...73,820,138
JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions
ISO belinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
JBrowse link
G Cdh9 cadherin 9 decreases expression
increases expression
ISO belinostat results in decreased expression of CDH9 mRNA
belinostat results in increased expression of CDH9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:66,280,422...66,367,121
Ensembl chr 2:66,228,117...66,367,121
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO belinostat results in decreased expression of CDK1 mRNA CTD PMID:19606018 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO belinostat results in decreased expression of CDK4 mRNA CTD PMID:19606018 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
ISO belinostat promotes the reaction [decitabine results in increased expression of CDKN1A mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CDKN1A protein]
belinostat results in increased expression of CDKN1A mRNA; belinostat results in increased expression of CDKN1A protein
CTD PMID:19234609 PMID:19606018 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A decreases expression ISO belinostat results in decreased expression of CDKN2A mRNA CTD PMID:19606018 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
JBrowse link
G Cdx4 caudal type homeo box 4 decreases expression ISO belinostat results in decreased expression of CDX4 mRNA CTD PMID:27188386 NCBI chr  X:68,326,874...68,335,461
Ensembl chr  X:68,326,874...68,335,461
JBrowse link
G Cep126 centrosomal protein 126 increases expression
multiple interactions
ISO belinostat results in increased expression of CEP126 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:5,200,576...5,267,740
Ensembl chr 8:5,218,509...5,267,467
JBrowse link
G Cep85l centrosomal protein 85-like increases expression
multiple interactions
ISO belinostat results in increased expression of CEP85L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516
JBrowse link
G Cfap119 cilia and flagella associated protein 119 increases expression ISO belinostat results in increased expression of CCDC189 mRNA CTD PMID:27188386 NCBI chr 1:182,197,171...182,216,936
Ensembl chr 1:182,192,947...182,202,338
JBrowse link
G Cfap20dc CFAP20 domain containing increases expression ISO belinostat results in increased expression of CFAP20DC mRNA CTD PMID:27188386 NCBI chr15:16,231,248...16,476,978
Ensembl chr15:16,231,299...16,476,977
JBrowse link
G Cftr CF transmembrane conductance regulator decreases expression ISO belinostat results in decreased expression of CFTR mRNA CTD PMID:27188386 NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
JBrowse link
G Chga chromogranin A increases expression
multiple interactions
ISO belinostat results in increased expression of CHGA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
JBrowse link
G Chodl chondrolectin multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
belinostat results in increased expression of CHODL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441
JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 increases expression
multiple interactions
ISO belinostat results in increased expression of CHRM3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit increases expression
multiple interactions
ISO belinostat results in increased expression of CHRNA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression ISO belinostat results in increased expression of CHST15 mRNA CTD PMID:27188386 NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
JBrowse link
G Cldn7 claudin 7 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
belinostat results in increased expression of CLDN7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
JBrowse link
G Clrn1 clarin 1 increases expression ISO belinostat results in increased expression of CLRN1 mRNA CTD PMID:27188386 NCBI chr 2:143,084,030...143,130,948
Ensembl chr 2:143,084,030...143,130,948
JBrowse link
G Clrn3 clarin 3 decreases expression ISO belinostat results in decreased expression of CLRN3 mRNA CTD PMID:27188386 NCBI chr 1:190,319,025...190,334,648
Ensembl chr 1:190,319,026...190,334,648
JBrowse link
G Clu clusterin multiple interactions
increases expression
ISO belinostat promotes the reaction [decitabine results in increased expression of CLU mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CLU protein]
belinostat results in increased expression of CLU mRNA; belinostat results in increased expression of CLU protein
CTD PMID:19234609 PMID:19606018 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
JBrowse link
G Cmpk2 cytidine/uridine monophosphate kinase 2 decreases expression ISO belinostat results in decreased expression of CMPK2 mRNA CTD PMID:27188386 NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183
JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA CTD PMID:27188386 NCBI chr  X:36,908,135...37,148,337
Ensembl chr  X:36,907,850...37,150,555
JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions
ISO belinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297
JBrowse link
G Cntn1 contactin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CNTN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
JBrowse link
G Cntn3 contactin 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CNTN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:134,842,266...135,125,613
JBrowse link
G Cntnap4 contactin associated protein family member 4 decreases expression ISO belinostat results in decreased expression of CNTNAP4 mRNA CTD PMID:27188386 NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656
JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA CTD PMID:27188386 NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
JBrowse link
G Coch cochlin decreases expression ISO belinostat results in decreased expression of COCH mRNA CTD PMID:27188386 NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
belinostat results in increased expression of COL1A2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Col26a1 collagen type XXVI alpha 1 chain decreases expression ISO belinostat results in decreased expression of COL26A1 mRNA CTD PMID:27188386 NCBI chr12:19,792,693...19,938,556
Ensembl chr12:19,792,728...19,938,556
JBrowse link
G Col6a6 collagen type VI alpha 6 chain decreases expression ISO belinostat results in decreased expression of COL6A6 mRNA CTD PMID:27188386 NCBI chr 8:106,318,010...106,473,419
Ensembl chr 8:106,306,422...106,473,472
JBrowse link
G Colec12 collectin sub-family member 12 increases expression ISO belinostat results in increased expression of COLEC12 mRNA CTD PMID:26272509 NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549
JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
belinostat results in increased expression of COMTD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,459,783...2,462,895
JBrowse link
G Cpne2 copine 2 decreases expression ISO belinostat results in decreased expression of CPNE2 mRNA CTD PMID:27188386 NCBI chr19:10,434,277...10,472,146
Ensembl chr19:10,434,277...10,471,820
JBrowse link
G Cpne4 copine 4 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
belinostat results in increased expression of CPNE4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068
JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions
ISO belinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445
JBrowse link
G Crb1 crumbs cell polarity complex component 1 increases expression ISO belinostat results in increased expression of CRB1 mRNA CTD PMID:27188386 NCBI chr13:50,801,484...50,989,261
Ensembl chr13:50,800,959...50,989,261
JBrowse link
G Crip1 cysteine rich protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA
belinostat results in increased expression of CRIP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620
JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CRYBG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392
JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
JBrowse link
G Ctps1 CTP synthase 1 decreases expression ISO belinostat results in decreased expression of CTPS1 mRNA CTD PMID:19606018 NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
JBrowse link
G Ctsk cathepsin K decreases expression ISO belinostat results in decreased expression of CTSK mRNA CTD PMID:27188386 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
JBrowse link
G Ctso cathepsin O decreases expression ISO belinostat results in decreased expression of CTSO mRNA CTD PMID:27188386 NCBI chr 2:167,230,407...167,254,761 JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 increases expression
multiple interactions
decreases expression
ISO belinostat results in increased expression of CXCL12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
belinostat results in decreased expression of CXCL12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 increases expression ISO belinostat results in increased expression of CXCL14 mRNA CTD PMID:26272509 NCBI chr17:8,317,933...8,325,956
Ensembl chr17:8,317,933...8,324,839
JBrowse link
G Cyfip1 cytoplasmic FMR1 interacting protein 1 decreases expression ISO belinostat results in decreased expression of CYFIP1 mRNA CTD PMID:27188386 NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP1B1 mRNA CTD PMID:26272509 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP26A1 mRNA CTD PMID:26272509 NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
JBrowse link
G Cyp39a1 cytochrome P450, family 39, subfamily a, polypeptide 1 increases expression ISO belinostat results in increased expression of CYP39A1 mRNA CTD PMID:27188386 NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
JBrowse link
G Cyth1 cytohesin 1 decreases expression ISO belinostat results in decreased expression of CYTH1 mRNA CTD PMID:27188386 NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of DACT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906
JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
belinostat results in decreased expression of DAZL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:10,695,572...10,712,443
Ensembl chr 9:10,695,592...10,712,323
JBrowse link
G Dcaf7 DDB1 and CUL4 associated factor 7 increases expression ISO belinostat results in increased expression of DCAF7 mRNA CTD PMID:27188386 NCBI chr10:90,974,095...90,996,275
Ensembl chr10:90,974,095...90,996,275
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA CTD PMID:27188386 NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
JBrowse link
G Dcdc2 doublecortin domain containing 2 decreases expression ISO belinostat results in decreased expression of DCDC2 mRNA CTD PMID:27188386 NCBI chr17:39,845,952...40,031,781
Ensembl chr17:39,845,952...40,030,743
JBrowse link
G Ddb2 damage specific DNA binding protein 2 decreases expression ISO belinostat results in decreased expression of DDB2 mRNA CTD PMID:29733868 NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
JBrowse link
G Ddc dopa decarboxylase decreases expression ISO belinostat results in decreased expression of DDC mRNA CTD PMID:27188386 NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
JBrowse link
G Ddx21 DExD-box helicase 21 decreases expression ISO belinostat results in decreased expression of DDX21 mRNA CTD PMID:19606018 NCBI chr20:30,534,319...30,554,513
Ensembl chr20:30,534,319...30,554,543
JBrowse link
G Defb1 defensin beta 1 decreases expression ISO belinostat results in decreased expression of DEFB1 mRNA CTD PMID:27188386 NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
JBrowse link
G Dennd1a DENN domain containing 1A decreases expression
multiple interactions
ISO belinostat results in decreased expression of DENND1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions
ISO belinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions
ISO belinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
JBrowse link
G Dgki diacylglycerol kinase, iota multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA CTD PMID:27188386 NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
JBrowse link
G Dhrs2 dehydrogenase/reductase 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA
belinostat results in increased expression of DHRS2 mRNA
CTD PMID:19606018 PMID:27188386 NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions
ISO belinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:92,395,189...93,234,521 JBrowse link
G Dio1 iodothyronine deiodinase 1 decreases expression ISO belinostat results in decreased expression of DIO1 mRNA CTD PMID:27188386 NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
JBrowse link
G Dkk1 dickkopf WNT signaling pathway inhibitor 1 increases expression ISO belinostat results in increased expression of DKK1 mRNA CTD PMID:26272509 NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO belinostat results in increased expression of DNAJB1 mRNA CTD PMID:19606018 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Dner delta/notch-like EGF repeat containing increases expression
multiple interactions
ISO belinostat results in increased expression of DNER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:85,586,985...85,902,820
Ensembl chr 9:85,586,987...85,902,637
JBrowse link
G Dock10 dedicator of cytokinesis 10 decreases expression ISO belinostat results in decreased expression of DOCK10 mRNA CTD PMID:27188386 NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525
JBrowse link
G Dok5 docking protein 5 increases expression ISO belinostat results in increased expression of DOK5 mRNA CTD PMID:26272509 NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
JBrowse link
G Dppa5 developmental pluripotency associated 5 increases expression
multiple interactions
ISO belinostat results in increased expression of DPPA5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:79,215,341...79,217,282
Ensembl chr 8:79,215,362...79,216,570
JBrowse link
G Dtx3l deltex E3 ubiquitin ligase 3L decreases expression ISO belinostat results in decreased expression of DTX3L mRNA CTD PMID:27188386 NCBI chr11:64,814,926...64,824,538
Ensembl chr11:64,814,926...64,824,538
JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression ISO belinostat results in increased expression of DUSP10 mRNA CTD PMID:26272509 NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO belinostat results in decreased expression of DUSP9 mRNA CTD PMID:27188386 NCBI chr  X:151,351,897...151,355,822
Ensembl chr  X:151,351,897...151,355,821
JBrowse link
G Dynlt5 dynein light chain Tctex-type family member 5 increases expression ISO belinostat results in increased expression of DYNLT5 mRNA CTD PMID:27188386 NCBI chr 5:117,735,509...117,758,221
Ensembl chr 5:117,735,439...117,757,588
JBrowse link
G E2f2 E2F transcription factor 2 decreases expression ISO belinostat results in decreased expression of E2F2 mRNA CTD PMID:26272509 NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
JBrowse link
G Eaf2 ELL associated factor 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA CTD PMID:27188386 NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
JBrowse link
G Echdc2 enoyl CoA hydratase domain containing 2 decreases expression ISO belinostat results in decreased expression of ECHDC2 mRNA CTD PMID:27188386 NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:122,916,134...122,934,859
JBrowse link
G Edn1 endothelin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions
ISO belinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
belinostat results in increased expression of EDNRB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 affects expression ISO belinostat affects the expression of EEF1A1 mRNA CTD PMID:27015953 NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
JBrowse link
G Efcab2 EF-hand calcium binding domain 2 decreases expression ISO belinostat results in decreased expression of EFCAB2 mRNA CTD PMID:27188386 NCBI chr13:90,152,002...90,237,918
Ensembl chr13:90,152,185...90,238,218
JBrowse link
G Efna1 ephrin A1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
belinostat results in increased expression of EFNA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA CTD PMID:27188386 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Eif4g2 eukaryotic translation initiation factor 4, gamma 2 decreases expression ISO belinostat results in decreased expression of EIF4G2 mRNA CTD PMID:19606018 NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions
ISO belinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:23,544,520...23,584,855
Ensembl chr17:23,544,568...23,584,848
JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression ISO belinostat results in increased expression of EPB41L5 mRNA CTD PMID:26272509 NCBI chr13:30,673,052...30,770,213
Ensembl chr13:30,669,764...30,768,360
JBrowse link
G Epcam epithelial cell adhesion molecule increases expression ISO belinostat results in increased expression of EPCAM mRNA CTD PMID:26272509 NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
JBrowse link
G Epdr1 ependymin related 1 decreases expression ISO belinostat results in decreased expression of EPDR1 mRNA CTD PMID:27188386 NCBI chr17:45,333,677...45,358,597
Ensembl chr17:45,333,956...45,358,594
JBrowse link
G Epha1 Eph receptor A1 increases expression
multiple interactions
ISO belinostat results in increased expression of EPHA1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
JBrowse link
G Epha3 Eph receptor A3 increases expression ISO belinostat results in increased expression of EPHA3 mRNA CTD PMID:26272509 NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
JBrowse link
G Epha7 Eph receptor A7 increases expression ISO belinostat results in increased expression of EPHA7 mRNA CTD PMID:26272509 NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
JBrowse link
G Ermap erythroblast membrane associated protein (Scianna blood group) decreases expression ISO belinostat results in decreased expression of ERMAP mRNA CTD PMID:27188386 NCBI chr 5:132,788,847...132,803,030
Ensembl chr 5:132,789,991...132,802,847
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions
ISO belinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
JBrowse link
G Etv5 ETS variant transcription factor 5 decreases expression ISO belinostat results in decreased expression of ETV5 mRNA CTD PMID:27188386 NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215
JBrowse link
G Exo1 exonuclease 1 decreases expression ISO belinostat results in decreased expression of EXO1 protein CTD PMID:29733868 NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
JBrowse link
G Ezh1 enhancer of zeste 1 polycomb repressive complex 2 subunit increases expression ISO belinostat results in increased expression of EZH1 mRNA CTD PMID:27188386 NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
JBrowse link
G F10 coagulation factor X decreases expression ISO belinostat results in decreased expression of F10 mRNA CTD PMID:27188386 NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
JBrowse link
G F13a1 coagulation factor XIII A1 chain increases expression ISO belinostat results in increased expression of F13A1 mRNA CTD PMID:27188386 NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression
increases expression
multiple interactions
ISO belinostat results in decreased expression of F2RL1 mRNA
belinostat results in increased expression of F2RL1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
JBrowse link
G Fabp1 fatty acid binding protein 1 decreases expression ISO belinostat results in decreased expression of FABP1 mRNA CTD PMID:27188386 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA CTD PMID:27188386 NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
JBrowse link
G Fam174b family with sequence similarity 174, member B decreases expression ISO belinostat results in decreased expression of FAM174B mRNA CTD PMID:27188386 NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:127,514,041...127,596,128
JBrowse link
G Fam222a family with sequence similarity 222, member A decreases expression
multiple interactions
ISO belinostat results in decreased expression of FAM222A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:41,982,064...42,033,085
Ensembl chr12:41,986,780...42,033,682
JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions
ISO belinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
JBrowse link
G Fancg FA complementation group G decreases expression ISO belinostat results in decreased expression of FANCG mRNA CTD PMID:29733868 NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029
JBrowse link
G Far2 fatty acyl CoA reductase 2 decreases expression ISO belinostat results in decreased expression of FAR2 mRNA CTD PMID:27188386 NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:181,007,622...181,087,255
JBrowse link
G Fbln1 fibulin 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of FBLN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
JBrowse link
G Fbln2 fibulin 2 decreases expression ISO belinostat results in decreased expression of FBLN2 mRNA CTD PMID:27188386 NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
JBrowse link
G Fbln7 fibulin 7 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA
belinostat results in decreased expression of FBLN7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:116,111,677...116,147,983
JBrowse link
G Fbn1 fibrillin 1 decreases expression ISO belinostat results in decreased expression of FBN1 mRNA CTD PMID:27188386 NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
JBrowse link
G Fbxo43 F-box protein 43 decreases expression
multiple interactions
ISO belinostat results in decreased expression of FBXO43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:67,333,161...67,346,751
Ensembl chr 7:67,333,162...67,346,751
JBrowse link
G Fbxw4 F-box and WD repeat domain containing 4 decreases expression ISO belinostat results in decreased expression of FBXW4 mRNA CTD PMID:27188386 NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163
JBrowse link
G Fgf4 fibroblast growth factor 4 increases expression
multiple interactions
ISO belinostat results in increased expression of FGF4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:200,023,937...200,027,793
Ensembl chr 1:200,024,056...200,025,466
JBrowse link
G Fgf9 fibroblast growth factor 9 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
belinostat results in decreased expression of FGF9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 increases expression
multiple interactions
ISO belinostat results in increased expression of FLT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
JBrowse link
G Fmo5 flavin containing dimethylaniline monoxygenase 5 decreases expression ISO belinostat results in decreased expression of FMO5 mRNA CTD PMID:27188386 NCBI chr 2:185,197,184...185,249,699
Ensembl chr 2:185,222,204...185,249,693
JBrowse link
G Folr1 folate receptor alpha decreases expression ISO belinostat results in decreased expression of FOLR1 mRNA CTD PMID:27188386 NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
JBrowse link
G Foxc2 forkhead box C2 increases expression ISO belinostat results in increased expression of FOXC2 mRNA CTD PMID:26272509 NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions
ISO belinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:114,334,693...114,337,788 JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions
ISO belinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:108,387,969...108,391,566
Ensembl chr 7:108,387,969...108,390,049
JBrowse link
G Foxo1 forkhead box O1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA
belinostat results in increased expression of FOXO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
JBrowse link
G Frem1 Fras1 related extracellular matrix 1 decreases expression ISO belinostat results in decreased expression of FREM1 mRNA CTD PMID:27188386 NCBI chr 5:97,321,275...97,469,523
Ensembl chr 5:97,322,538...97,469,543
JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA CTD PMID:27188386 NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108
JBrowse link
G Fut9 fucosyltransferase 9 increases expression ISO belinostat results in increased expression of FUT9 mRNA CTD PMID:27188386 NCBI chr 5:39,351,815...39,565,256
Ensembl chr 5:39,351,819...39,565,130
JBrowse link
G Fzd5 frizzled class receptor 5 decreases expression ISO belinostat results in decreased expression of FZD5 mRNA CTD PMID:26272509 NCBI chr 9:66,117,370...66,119,127
Ensembl chr 9:66,113,112...66,121,457
JBrowse link
G Fzd7 frizzled class receptor 7 increases expression
multiple interactions
ISO belinostat results in increased expression of FZD7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GABRB3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
JBrowse link
G Gad1 glutamate decarboxylase 1 increases expression
multiple interactions
ISO belinostat results in increased expression of GAD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO belinostat results in increased expression of GADD45A mRNA; belinostat results in increased expression of GADD45A protein CTD PMID:29733868 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Galnt17 polypeptide N-acetylgalactosaminyltransferase 17 decreases expression ISO belinostat results in decreased expression of GALNT17 mRNA CTD PMID:27188386 NCBI chr12:25,323,839...25,780,036
Ensembl chr12:25,322,701...25,781,290
JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
belinostat results in increased expression of GALNT3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
JBrowse link
G Gap43 growth associated protein 43 increases expression
multiple interactions
ISO belinostat results in increased expression of GAP43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
JBrowse link
G Gata3 GATA binding protein 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GATA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
JBrowse link
G Gba3 glucosylceramidase beta 3 decreases expression ISO belinostat results in decreased expression of GBA3 mRNA CTD PMID:27188386 NCBI chr14:60,575,368...60,662,952
Ensembl chr14:60,574,976...60,721,653
JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 decreases expression ISO belinostat results in decreased expression of GBE1 mRNA CTD PMID:27188386 NCBI chr11:8,734,806...9,000,226
Ensembl chr11:8,734,820...9,000,210
JBrowse link
G Gcat glycine C-acetyltransferase decreases expression ISO belinostat results in decreased expression of GCAT mRNA CTD PMID:27188386 NCBI chr 7:110,595,126...110,601,474
Ensembl chr 7:110,595,091...110,601,473
JBrowse link
G Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA CTD PMID:27188386 NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:152,110,253...152,128,711
JBrowse link
G Gfra1 GDNF family receptor alpha 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA
belinostat results in decreased expression of GFRA1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:257,315,682...257,552,004 JBrowse link
G Glb1l3 galactosidase, beta 1-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GLB1L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:25,179,165...25,220,904
Ensembl chr 8:25,179,165...25,220,904
JBrowse link
G Gldn gliomedin increases expression ISO belinostat results in increased expression of GLDN mRNA CTD PMID:27188386 NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196
JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression ISO belinostat results in decreased expression of GLIS3 mRNA CTD PMID:26272509 NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899
JBrowse link
G Glt8d2 glycosyltransferase 8 domain containing 2 decreases expression ISO belinostat results in decreased expression of GLT8D2 mRNA CTD PMID:27188386 NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:21,029,525...21,081,080
JBrowse link
G Gng11 G protein subunit gamma 11 increases expression ISO belinostat results in increased expression of GNG11 mRNA CTD PMID:26272509 NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442
JBrowse link
G Gpc6 glypican 6 decreases expression
multiple interactions
ISO belinostat results in decreased expression of GPC6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
JBrowse link
G Gpr143 G protein-coupled receptor 143 decreases expression ISO belinostat results in decreased expression of GPR143 mRNA CTD PMID:27188386 NCBI chr  X:22,002,914...22,027,720
Ensembl chr  X:22,002,914...22,027,715
JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression ISO belinostat results in decreased expression of GPR27 mRNA CTD PMID:27188386 NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
JBrowse link
G Gpx7 glutathione peroxidase 7 decreases expression ISO belinostat results in decreased expression of GPX7 mRNA CTD PMID:27188386 NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
ISO belinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions
ISO belinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:147,774,160...147,806,338
Ensembl chr 5:147,774,160...147,806,160
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 increases expression ISO belinostat results in increased expression of GRIA3 mRNA CTD PMID:27188386 NCBI chr  X:120,238,515...120,504,106
Ensembl chr  X:120,238,534...120,504,096
JBrowse link
G Grik1 glutamate ionotropic receptor kainate type subunit 1 increases expression ISO belinostat results in increased expression of GRIK1 mRNA CTD PMID:27188386 NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
JBrowse link
G Grk6 G protein-coupled receptor kinase 6 decreases expression ISO belinostat results in decreased expression of GRK6 mRNA CTD PMID:27188386 NCBI chr17:9,177,018...9,192,644
Ensembl chr17:9,177,019...9,192,644
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta increases phosphorylation ISO belinostat results in increased phosphorylation of GSK3B protein CTD PMID:23671600 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G H1f0 H1.0 linker histone increases expression ISO belinostat results in increased expression of H1-0 mRNA CTD PMID:19606018 PMID:27188386 NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
JBrowse link
G H1f10 H1.10 linker histone increases expression ISO belinostat results in increased expression of H1-10 mRNA CTD PMID:19606018 NCBI chr 4:120,440,515...120,444,705
Ensembl chr 4:120,440,870...120,441,448
JBrowse link
G H2bc12 H2B clustered histone 12 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
belinostat results in decreased expression of H2BC12 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:42,485,746...42,486,126 JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
belinostat results in increased expression of HAPLN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
JBrowse link
G Hapln4 hyaluronan and proteoglycan link protein 4 decreases expression ISO belinostat results in decreased expression of HAPLN4 mRNA CTD PMID:27188386 NCBI chr16:19,333,106...19,341,243
Ensembl chr16:19,333,106...19,341,243
JBrowse link
G Hbe1 hemoglobin subunit epsilon 1 decreases expression ISO belinostat results in decreased expression of HBE1 mRNA CTD PMID:27188386 NCBI chr 1:158,282,931...158,458,855
Ensembl chr 1:158,282,936...158,284,391
JBrowse link
G Heg1 heart development protein with EGF-like domains 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of HEG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
JBrowse link
G Hes5 hes family bHLH transcription factor 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
belinostat results in decreased expression of HES5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:2,191,852...2,193,957
Ensembl chr16:2,191,852...2,193,957
JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
belinostat results in increased expression of HEY2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
JBrowse link
G Hgd homogentisate 1, 2-dioxygenase decreases expression ISO belinostat results in decreased expression of HGD mRNA CTD PMID:27188386 NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
JBrowse link
G Hhex hematopoietically expressed homeobox increases expression
multiple interactions
ISO belinostat results in increased expression of HHEX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
JBrowse link
G Hist1h2bd histone cluster 1 H2B family member D decreases expression
multiple interactions
ISO belinostat results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:42,792,887...42,793,268 JBrowse link
G Hkdc1 hexokinase domain containing 1 decreases expression ISO belinostat results in decreased expression of HKDC1 mRNA CTD PMID:27188386 NCBI chr20:30,335,322...30,373,792 JBrowse link
G Hmx2 H6 family homeobox 2 increases expression
multiple interactions
ISO belinostat results in increased expression of HMX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:186,319,110...186,326,771
JBrowse link
G Homer2 homer scaffold protein 2 decreases expression ISO belinostat results in decreased expression of HOMER2 mRNA CTD PMID:26272509 NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:135,567,414...135,659,772
JBrowse link
G Hoxd3 homeo box D3 increases expression ISO belinostat results in increased expression of HOXD3 mRNA CTD PMID:27188386 NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
JBrowse link
G Hoxd4 homeo box D4 increases expression ISO belinostat results in increased expression of HOXD4 mRNA CTD PMID:27188386 NCBI chr 3:59,614,464...59,634,042
Ensembl chr 3:59,614,464...59,631,528
JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like increases expression
multiple interactions
ISO belinostat results in increased expression of HPDL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO belinostat results in increased expression of HPGD mRNA CTD PMID:26272509 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
JBrowse link
G Hpx hemopexin decreases expression ISO belinostat results in decreased expression of HPX mRNA CTD PMID:27188386 NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
JBrowse link
G Hunk hormonally upregulated Neu-associated kinase decreases expression ISO belinostat results in decreased expression of HUNK mRNA CTD PMID:27188386 NCBI chr11:29,641,051...29,758,392
Ensembl chr11:29,640,775...29,757,526
JBrowse link
G Hus1 HUS1 checkpoint clamp component increases expression ISO belinostat results in increased expression of HUS1 mRNA CTD PMID:29733868 NCBI chr14:83,688,702...83,703,466
Ensembl chr14:83,688,708...83,703,442
JBrowse link
G Hyi hydroxypyruvate isomerase decreases expression ISO belinostat results in decreased expression of HYI mRNA CTD PMID:27188386 NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251
JBrowse link
G Ice2 interactor of little elongation complex ELL subunit 2 increases expression ISO belinostat results in increased expression of ICE2 mRNA CTD PMID:27188386 NCBI chr 8:70,043,419...70,085,217
Ensembl chr 8:70,043,424...70,084,995
JBrowse link
G Id4 inhibitor of DNA binding 4, HLH protein increases expression
multiple interactions
ISO belinostat results in increased expression of ID4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of IDH3A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
JBrowse link
G Idnk Idnk, gluconokinase decreases expression ISO belinostat results in decreased expression of IDNK mRNA CTD PMID:27188386 NCBI chr17:6,483,575...6,490,780
Ensembl chr17:6,483,576...6,490,905
JBrowse link
G Ido1 indoleamine 2,3-dioxygenase 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA CTD PMID:27188386 NCBI chr16:67,430,684...67,442,459
Ensembl chr16:67,430,578...67,442,730
JBrowse link
G Ifit3 interferon-induced protein with tetratricopeptide repeats 3 decreases expression ISO belinostat results in decreased expression of IFIT3 mRNA CTD PMID:27188386 NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
JBrowse link
G Ifng interferon gamma multiple interactions ISO belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] CTD PMID:29301935 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Ifngr1 interferon gamma receptor 1 increases expression ISO belinostat results in increased expression of IFNGR1 mRNA CTD PMID:19606018 NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
JBrowse link
G Igf1 insulin-like growth factor 1 increases expression ISO belinostat results in increased expression of IGF1 mRNA CTD PMID:23671600 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
JBrowse link
G Il15 interleukin 15 multiple interactions ISO belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein] CTD PMID:29301935 NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
JBrowse link
G Il17d interleukin 17D decreases expression ISO belinostat results in decreased expression of IL17D mRNA CTD PMID:27188386 NCBI chr15:31,665,795...31,688,840 JBrowse link
G Il17rb interleukin 17 receptor B decreases expression ISO belinostat results in decreased expression of IL17RB mRNA CTD PMID:27188386 NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,180,432...5,194,125
JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions
ISO belinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:2,228,467...2,295,126
Ensembl chr16:2,228,287...2,292,556
JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions
ISO belinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
JBrowse link
G Il4r interleukin 4 receptor decreases expression ISO belinostat results in decreased expression of IL4R mRNA CTD PMID:27188386 NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
JBrowse link
G Il6 interleukin 6 increases expression ISO belinostat results in increased expression of IL6 mRNA CTD PMID:23671600 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Impg1 interphotoreceptor matrix proteoglycan 1 increases expression ISO belinostat results in increased expression of IMPG1 mRNA CTD PMID:27188386 NCBI chr 8:81,243,624...81,389,722
Ensembl chr 8:81,243,624...81,389,722
JBrowse link
G Incenp inner centromere protein decreases expression ISO belinostat results in decreased expression of INCENP mRNA CTD PMID:19606018 NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
JBrowse link
G Inhba inhibin subunit beta A increases expression
multiple interactions
ISO belinostat results in increased expression of INHBA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
JBrowse link
G Inpp1 inositol polyphosphate-1-phosphatase decreases expression ISO belinostat results in decreased expression of INPP1 mRNA CTD PMID:27188386 NCBI chr 9:48,688,037...48,717,793
Ensembl chr 9:48,669,901...48,717,793
JBrowse link
G Irx1 iroquois homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of IRX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444
JBrowse link
G Irx2 iroquois homeobox 2 increases expression
multiple interactions
ISO belinostat results in increased expression of IRX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:30,660,960...30,666,378
Ensembl chr 1:30,660,960...30,666,378
JBrowse link
G Itga2 integrin subunit alpha 2 increases expression ISO belinostat results in increased expression of ITGA2 mRNA CTD PMID:27188386 NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
JBrowse link
G Itga3 integrin subunit alpha 3 decreases expression ISO belinostat results in decreased expression of ITGA3 mRNA CTD PMID:27188386 NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression ISO belinostat results in decreased expression of ITGB5 mRNA CTD PMID:26272509 NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
JBrowse link
G Itih5 inter-alpha-trypsin inhibitor heavy chain 5 increases expression
multiple interactions
ISO belinostat results in increased expression of ITIH5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:68,248,115...68,352,216 JBrowse link
G Itm2a integral membrane protein 2A increases expression ISO belinostat results in increased expression of ITM2A mRNA CTD PMID:26272509 NCBI chr  X:72,486,383...72,492,344
Ensembl chr  X:72,486,381...72,492,363
JBrowse link
G Itpripl2 ITPRIP like 2 decreases expression ISO belinostat results in decreased expression of ITPRIPL2 mRNA CTD PMID:27188386 NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950
JBrowse link
G Jazf1 JAZF zinc finger 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA CTD PMID:27188386 NCBI chr 4:81,879,501...82,183,241
Ensembl chr 4:81,881,061...82,183,100
JBrowse link
G Kansl1l KAT8 regulatory NSL complex subunit 1-like decreases expression ISO belinostat results in decreased expression of KANSL1L mRNA CTD PMID:27188386 NCBI chr 9:68,211,151...68,316,992
Ensembl chr 9:68,211,189...68,300,222
JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 decreases expression
multiple interactions
ISO belinostat results in decreased expression of KCNJ13 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112
JBrowse link
G Kcnj2 potassium inwardly-rectifying channel, subfamily J, member 2 decreases expression ISO belinostat results in decreased expression of KCNJ2 mRNA CTD PMID:27188386 NCBI chr10:96,060,849...96,071,401
Ensembl chr10:96,060,821...96,071,445
JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
JBrowse link
G Kdm4c lysine demethylase 4C increases expression ISO belinostat results in increased expression of KDM4C mRNA CTD PMID:27188386 NCBI chr 5:88,100,710...88,306,821
Ensembl chr 5:88,100,733...88,306,818
JBrowse link
G Kdr kinase insert domain receptor increases expression
multiple interactions
ISO belinostat results in increased expression of KDR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 decreases expression ISO belinostat results in decreased expression of KEAP1 mRNA CTD PMID:19606018 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions
ISO belinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
JBrowse link
G Klf9 Kruppel-like factor 9 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA CTD PMID:27188386 NCBI chr 1:220,700,108...220,725,029
Ensembl chr 1:220,700,108...220,725,037
JBrowse link
G Klhl18 kelch-like family member 18 increases expression ISO belinostat results in increased expression of KLHL18 mRNA CTD PMID:27188386 NCBI chr 8:110,400,679...110,459,442
Ensembl chr 8:110,400,681...110,459,323
JBrowse link
G Kpnb1 karyopherin subunit beta 1 decreases expression ISO belinostat results in decreased expression of KPNB1 mRNA CTD PMID:19606018 NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605
JBrowse link
G Krt18 keratin 18 increases expression
multiple interactions
ISO belinostat results in increased expression of KRT18 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
JBrowse link
G Lactb lactamase, beta multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
belinostat results in increased expression of LACTB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539
JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions
ISO belinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
JBrowse link
G Lctl lactase-like decreases expression
multiple interactions
ISO belinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:64,618,350...64,639,357
JBrowse link
G Lgi1 leucine-rich, glioma inactivated 1 increases expression ISO belinostat results in increased expression of LGI1 mRNA CTD PMID:26272509 NCBI chr 1:236,043,376...236,084,270
Ensembl chr 1:236,042,954...236,084,616
JBrowse link
G Lhx2 LIM homeobox 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LHX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
JBrowse link
G Lhx8 LIM homeobox 8 increases expression
multiple interactions
ISO belinostat results in increased expression of LHX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:243,244,958...243,269,631
Ensembl chr 2:243,244,961...243,269,416
JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA CTD PMID:27188386 NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:41,112,579...41,425,185
Ensembl chr14:41,114,803...41,425,191
JBrowse link
G Lipg lipase G, endothelial type multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA CTD PMID:27188386 NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression ISO belinostat results in decreased expression of LMAN1 mRNA CTD PMID:26272509 NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
JBrowse link
G Lmo2 LIM domain only 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LMO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:90,355,234...90,377,970
Ensembl chr 3:90,365,883...90,377,953
JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222
JBrowse link
G LOC100302372 hypothetical protein LOC100302372 increases expression
multiple interactions
ISO belinostat results in increased expression of KIAA0040 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:72,274,519...72,312,103
Ensembl chr13:72,274,552...72,312,103
JBrowse link
G LOC100361016 oocyte specific homeobox 5-like increases expression
multiple interactions
ISO belinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:86,483,893...86,484,900
Ensembl chr  X:86,483,893...86,484,954
JBrowse link
G LOC100361913 rCG54286-like multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA CTD PMID:27188386 NCBI chr 1:84,549,827...84,550,786
Ensembl chr 1:84,549,831...84,550,664
JBrowse link
G LOC100362342 rCG47764-like decreases expression ISO belinostat results in decreased expression of C10ORF143 mRNA CTD PMID:27188386 NCBI chr 1:192,184,440...192,222,676
Ensembl chr 1:192,184,445...192,222,398
JBrowse link
G LOC100362814 hypothetical protein LOC100362814 decreases expression
multiple interactions
ISO belinostat results in decreased expression of KIAA1549L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:90,506,559...90,782,427
Ensembl chr 3:90,510,942...90,781,894
JBrowse link
G LOC100912195 protein BEX1-like increases expression
multiple interactions
ISO belinostat results in increased expression of BEX5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:110,047,861...110,051,812 JBrowse link
G LOC103690190 histone H2A type 1-E multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA CTD PMID:27188386 NCBI chr17:42,707,863...42,708,420 JBrowse link
G Lpar1 lysophosphatidic acid receptor 1 decreases expression ISO belinostat results in decreased expression of LPAR1 mRNA CTD PMID:27188386 NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression ISO belinostat results in increased expression of LPAR6 mRNA CTD PMID:26272509 NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
JBrowse link
G Lrrc10b leucine rich repeat containing 10B decreases expression ISO belinostat results in decreased expression of LRRC10B mRNA CTD PMID:27188386 NCBI chr 1:207,096,471...207,097,699
Ensembl chr 1:207,022,919...207,098,045
JBrowse link
G Lrrc17 leucine rich repeat containing 17 increases expression ISO belinostat results in increased expression of LRRC17 mRNA CTD PMID:26272509 NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845
JBrowse link
G Lrrc55 leucine rich repeat containing 55 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
belinostat results in decreased expression of LRRC55 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:70,265,934...70,280,689
Ensembl chr 3:70,265,936...70,278,639
JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 increases expression
multiple interactions
ISO belinostat results in increased expression of LRRN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
JBrowse link
G LRRTM1 leucine rich repeat transmembrane neuronal 1 increases expression
multiple interactions
ISO belinostat results in increased expression of LRRTM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:109,701,815...109,718,924
Ensembl chr 4:109,701,815...109,717,184
JBrowse link
G Lyzl6 lysozyme-like 6 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
belinostat results in increased expression of LYZL6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:88,544,342...88,549,177
Ensembl chr10:88,544,342...88,549,177
JBrowse link
G Macc1 MET transcriptional regulator MACC1 increases expression
multiple interactions
ISO belinostat results in increased expression of MACC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255
JBrowse link
G Macroh2a1 macroH2A.1 histone multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
belinostat results in decreased expression of MACROH2A1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072
JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 increases expression
multiple interactions
ISO belinostat results in increased expression of MAGI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:14,388,322...15,870,036
Ensembl chr 4:14,386,399...15,870,240
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO belinostat results in increased expression of MAP1LC3B mRNA CTD PMID:19606018 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Map3k5 mitogen-activated protein kinase kinase kinase 5 decreases expression ISO belinostat results in decreased expression of MAP3K5 mRNA CTD PMID:27188386 NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
JBrowse link
G Map3k8 mitogen-activated protein kinase kinase kinase 8 increases expression ISO belinostat results in increased expression of MAP3K8 mRNA CTD PMID:27188386 NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
JBrowse link
G Map6 microtubule-associated protein 6 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MAP6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:153,568,019...153,634,415
Ensembl chr 1:153,568,368...153,634,414
JBrowse link
G Map7d2 MAP7 domain containing 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MAP7D2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:35,372,453...35,488,073
Ensembl chr  X:35,372,700...35,488,091
JBrowse link
G Marveld1 MARVEL domain containing 1 decreases expression ISO belinostat results in decreased expression of MARVELD1 mRNA CTD PMID:27188386 NCBI chr 1:240,954,452...240,958,384
Ensembl chr 1:240,954,452...240,958,384
JBrowse link
G Mbnl3 muscleblind-like splicing regulator 3 increases expression
multiple interactions
ISO belinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:130,641,942...130,737,179
Ensembl chr  X:130,648,538...130,737,056
JBrowse link
G Mchr1 melanin-concentrating hormone receptor 1 decreases expression ISO belinostat results in decreased expression of MCHR1 mRNA CTD PMID:27188386 NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
JBrowse link
G Mcm3 minichromosome maintenance complex component 3 decreases expression ISO belinostat results in decreased expression of MCM3 mRNA CTD PMID:19606018 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO belinostat results in decreased expression of MCM7 mRNA CTD PMID:19606018 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
JBrowse link
G Mcoln3 mucolipin TRP cation channel 3 increases expression
multiple interactions
ISO belinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:234,966,010...235,043,047
Ensembl chr 2:234,966,010...235,043,047
JBrowse link
G Meox1 mesenchyme homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of MEOX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
JBrowse link
G Mettl7b methyltransferase like 7B decreases expression ISO belinostat results in decreased expression of METTL7B mRNA CTD PMID:27188386 NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,388,879...1,391,526
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression
multiple interactions
ISO belinostat results in decreased expression of MFNG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653
JBrowse link
G Mgam maltase-glucoamylase decreases expression ISO belinostat results in decreased expression of MGAM mRNA CTD PMID:27188386 NCBI chr 4:69,624,024...69,715,782
Ensembl chr 4:69,446,150...69,692,715
JBrowse link
G Miat myocardial infarction associated transcript decreases expression
multiple interactions
ISO belinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:44,414,620...44,429,852 JBrowse link
G Mlana melan-A decreases expression ISO belinostat results in decreased expression of MLANA mRNA CTD PMID:27188386 NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343
JBrowse link
G Mlh1 mutL homolog 1 multiple interactions ISO belinostat promotes the reaction [decitabine results in increased expression of MLH1 protein] CTD PMID:19259094 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
JBrowse link
G Mpg N-methylpurine-DNA glycosylase increases expression ISO belinostat results in increased expression of MPG mRNA CTD PMID:29733868 NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
JBrowse link
G Mpped2 metallophosphoesterase domain containing 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of MPPED2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:93,180,833...93,355,605
Ensembl chr 3:93,181,167...93,355,618
JBrowse link
G Msx1 msh homeobox 1 increases expression
multiple interactions
ISO belinostat results in increased expression of MSX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:72,961,170...72,964,970
Ensembl chr14:72,961,148...72,964,966
JBrowse link
G Msx2 msh homeobox 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
belinostat results in increased expression of MSX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
JBrowse link
G Mthfs methenyltetrahydrofolate synthetase decreases expression ISO belinostat results in decreased expression of MTHFS mRNA CTD PMID:27188386 NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:89,729,508...89,799,089
JBrowse link
G Muc15 mucin 15, cell surface associated multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
belinostat results in increased expression of MUC15 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:97,294,783...97,307,090
JBrowse link
G Mylip myosin regulatory light chain interacting protein increases expression
multiple interactions
ISO belinostat results in increased expression of MYLIP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295
JBrowse link
G Mylk myosin light chain kinase decreases expression ISO belinostat results in decreased expression of MYLK mRNA CTD PMID:26272509 NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
JBrowse link
G Myo3b myosin IIIB increases expression ISO belinostat results in increased expression of MYO3B mRNA CTD PMID:26272509 NCBI chr 3:54,873,704...55,226,189
Ensembl chr 3:54,820,251...55,227,373
JBrowse link
G Myof myoferlin increases expression ISO belinostat results in increased expression of MYOF mRNA CTD PMID:26272509 NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
JBrowse link
G Nanog Nanog homeobox increases expression
multiple interactions
ISO belinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
JBrowse link
G Nanos1 nanos C2HC-type zinc finger 1 decreases expression ISO belinostat results in decreased expression of NANOS1 mRNA CTD PMID:27188386 NCBI chr 1:259,897,659...259,901,501
Ensembl chr 1:259,897,939...259,898,730
JBrowse link
G Nav3 neuron navigator 3 increases expression ISO belinostat results in increased expression of NAV3 mRNA CTD PMID:26272509 NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698
JBrowse link
G Ncald neurocalcin delta decreases expression
multiple interactions
ISO belinostat results in decreased expression of NCALD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:68,534,421...68,964,496
JBrowse link
G Ncan neurocan decreases expression ISO belinostat results in decreased expression of NCAN mRNA CTD PMID:26272509 NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
JBrowse link
G Ndp norrin cystine knot growth factor NDP decreases expression
multiple interactions
ISO belinostat results in decreased expression of NDP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:5,796,487...5,820,934
Ensembl chr  X:5,796,487...5,820,934
JBrowse link
G Nefl neurofilament light chain increases expression ISO belinostat results in increased expression of NEFL mRNA CTD PMID:26272509 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
JBrowse link
G Negr1 neuronal growth regulator 1 increases expression ISO belinostat results in increased expression of NEGR1 mRNA CTD PMID:27188386 NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:245,624,435...246,356,730
JBrowse link
G Nell2 neural EGFL like 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:126,343,089...126,662,694
Ensembl chr 7:126,198,851...126,733,503
JBrowse link
G Neto2 neuropilin and tolloid like 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NETO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:21,344,299...21,418,182
Ensembl chr19:21,344,289...21,417,023
JBrowse link
G Nexmif neurite extension and migration factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA CTD PMID:27188386 NCBI chr  X:69,088,076...69,219,253
Ensembl chr  X:69,088,076...69,112,930
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
increases expression
ISO Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein] CTD PMID:18223231 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression
multiple interactions
ISO belinostat results in increased expression of NFKBIA protein
Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]
CTD PMID:18223231 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Ngef neuronal guanine nucleotide exchange factor multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA CTD PMID:27188386 NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914
JBrowse link
G Nipal2 NIPA-like domain containing 2 decreases expression ISO belinostat results in decreased expression of NIPAL2 mRNA CTD PMID:27188386 NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:65,774,477...65,884,807
JBrowse link
G Nlgn3 neuroligin 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA
belinostat results in decreased expression of NLGN3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:66,427,926...66,457,378
Ensembl chr  X:66,429,458...66,451,876
JBrowse link
G Nme8 NME/NM23 family member 8 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA
belinostat results in increased expression of NME8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:45,237,022...45,304,948
Ensembl chr17:45,238,120...45,304,948
JBrowse link
G Nmi N-myc (and STAT) interactor increases expression
multiple interactions
ISO belinostat results in increased expression of NMI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
JBrowse link
G Noct nocturnin multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA CTD PMID:27188386 NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
JBrowse link
G Nog noggin increases expression
multiple interactions
ISO belinostat results in increased expression of NOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EOLA2-DT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH11Y mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIFO mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO1B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
JBrowse link
G Nol4 nucleolar protein 4 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NOL4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:13,932,499...14,294,873
Ensembl chr18:13,932,510...14,296,286
JBrowse link
G Npffr2 neuropeptide FF receptor 2 increases expression
multiple interactions
ISO belinostat results in increased expression of NPFFR2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr14:18,513,277...18,521,919
Ensembl chr14:18,513,277...18,521,919
JBrowse link
G Npr3 natriuretic peptide receptor 3 increases expression ISO belinostat results in increased expression of NPR3 mRNA CTD PMID:26272509 NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
JBrowse link
G Npy neuropeptide Y increases expression
multiple interactions
ISO belinostat results in increased expression of NPY mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
belinostat results in increased expression of NQO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nrp1 neuropilin 1 increases expression
multiple interactions
ISO belinostat results in increased expression of NRP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
JBrowse link
G Nrxn2 neurexin 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NRXN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
JBrowse link
G Nsun7 NOP2/Sun RNA methyltransferase family member 7 decreases expression ISO belinostat results in decreased expression of NSUN7 mRNA CTD PMID:27188386 NCBI chr14:41,877,500...41,935,238
Ensembl chr14:41,879,293...41,934,949
JBrowse link
G Ntrk3 neurotrophic receptor tyrosine kinase 3 increases expression ISO belinostat results in increased expression of NTRK3 mRNA CTD PMID:27188386 NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
JBrowse link
G Nucb2 nucleobindin 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of NUCB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
JBrowse link
G Nudt12 nudix hydrolase 12 increases expression ISO belinostat results in increased expression of NUDT12 mRNA CTD PMID:27188386 NCBI chr 9:98,741,627...98,755,039
Ensembl chr 9:98,742,360...98,755,039
JBrowse link
G Nwd2 NACHT and WD repeat domain containing 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA CTD PMID:27188386 NCBI chr14:44,480,049...44,671,417
Ensembl chr14:44,482,287...44,670,299
JBrowse link
G Nxph2 neurexophilin 2 decreases expression ISO belinostat results in decreased expression of NXPH2 mRNA CTD PMID:26272509 NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:5,756,621...5,987,008
JBrowse link
G Ociad2 OCIA domain containing 2 decreases expression ISO belinostat results in decreased expression of OCIAD2 mRNA CTD PMID:27188386 NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265
JBrowse link
G Odc1 ornithine decarboxylase 1 increases expression ISO belinostat results in increased expression of ODC1 mRNA CTD PMID:19606018 NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
JBrowse link
G Ogg1 8-oxoguanine DNA glycosylase decreases expression ISO belinostat results in decreased expression of OGG1 mRNA; belinostat results in decreased expression of OGG1 protein CTD PMID:29733868 NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
JBrowse link
G Olfm3 olfactomedin 3 increases expression ISO belinostat results in increased expression of OLFM3 mRNA CTD PMID:26272509 NCBI chr 2:202,729,610...202,952,120
Ensembl chr 2:202,729,936...202,952,112
JBrowse link
G Olfml3 olfactomedin-like 3 increases expression
multiple interactions
ISO belinostat results in increased expression of OLFML3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:191,244,221...191,247,050
JBrowse link
G Oplah 5-oxoprolinase (ATP-hydrolysing) multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA CTD PMID:27188386 NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:108,011,475...108,035,297
JBrowse link
G Pa2g4 proliferation-associated 2G4 decreases expression ISO belinostat results in decreased expression of PA2G4 mRNA CTD PMID:19606018 NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
increases expression
multiple interactions
ISO belinostat results in increased cleavage of PARP1 protein
belinostat results in increased expression of PARP1 mRNA; belinostat results in increased expression of PARP1 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]
CTD PMID:18223231 PMID:29733868 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Parp9 poly (ADP-ribose) polymerase family, member 9 decreases expression ISO belinostat results in decreased expression of PARP9 mRNA CTD PMID:27188386 NCBI chr11:64,780,977...64,814,995
Ensembl chr11:64,780,981...64,815,455
JBrowse link
G Parvb parvin, beta decreases expression ISO belinostat results in decreased expression of PARVB mRNA CTD PMID:27188386 NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766
JBrowse link
G Pax3 paired box 3 increases expression
multiple interactions
ISO belinostat results in increased expression of PAX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
JBrowse link
G Pax7 paired box 7 increases expression
multiple interactions
ISO belinostat results in increased expression of PAX7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:151,999,092...152,097,979
JBrowse link
G Pbx2 PBX homeobox 2 decreases expression ISO belinostat results in decreased expression of PBX2 mRNA CTD PMID:27188386 NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425
JBrowse link
G Pcdh10 protocadherin 10 increases expression
multiple interactions
ISO belinostat results in increased expression of PCDH10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:128,617,174...128,677,190
JBrowse link
G Pcdh7 protocadherin 7 decreases expression ISO belinostat results in decreased expression of PCDH7 mRNA CTD PMID:27188386 NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051
Ensembl chr14:52,475,610...52,902,051
JBrowse link
G Pcdh8 protocadherin 8 increases expression ISO belinostat results in increased expression of PCDH8 mRNA CTD PMID:26272509 NCBI chr15:55,198,475...55,203,021
Ensembl chr15:55,198,459...55,205,872
JBrowse link
G Pcsk9 proprotein convertase subtilisin/kexin type 9 decreases expression ISO belinostat results in decreased expression of PCSK9 mRNA CTD PMID:27188386 NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
JBrowse link
G Pde10a phosphodiesterase 10A decreases expression
multiple interactions
ISO belinostat results in decreased expression of PDE10A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
JBrowse link
G Pde7b phosphodiesterase 7B increases expression ISO belinostat results in increased expression of PDE7B mRNA CTD PMID:27188386 NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900
JBrowse link
G Pdgfa platelet derived growth factor subunit A multiple interactions
increases expression
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA
belinostat results in increased expression of PDGFA mRNA
belinostat results in decreased expression of PDGFA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
JBrowse link
G Pdlim1 PDZ and LIM domain 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA
belinostat results in increased expression of PDLIM1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076
JBrowse link
G Pdpn podoplanin increases expression
multiple interactions
ISO belinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
JBrowse link
G Peg10 paternally expressed 10 increases expression ISO belinostat results in increased expression of PEG10 mRNA CTD PMID:19606018 NCBI chr 4:32,842,394...32,855,641 JBrowse link
G Pex13 peroxisomal biogenesis factor 13 increases expression ISO belinostat results in increased expression of PEX13 mRNA CTD PMID:27188386 NCBI chr14:97,602,829...97,621,233
Ensembl chr14:97,603,539...97,621,262
JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 increases expression ISO belinostat results in increased expression of PHLDA1 mRNA CTD PMID:26272509 NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836
JBrowse link
G Piezo1 piezo-type mechanosensitive ion channel component 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA
belinostat results in decreased expression of PIEZO1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501
JBrowse link
G Pifo primary cilia formation increases expression
multiple interactions
ISO belinostat results in increased expression of PIFO mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIFO mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:193,475,782...193,493,139
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase increases expression ISO belinostat results in increased expression of PIM1 mRNA CTD PMID:26272509 NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
JBrowse link
G Pipox pipecolic acid and sarcosine oxidase increases expression
multiple interactions
ISO belinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO belinostat results in increased expression of PITX2 mRNA CTD PMID:26272509 NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
JBrowse link
G Pkdcc protein kinase domain containing, cytoplasmic increases expression
multiple interactions
ISO belinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:11,455,686...11,465,002
Ensembl chr 6:11,455,686...11,465,556
JBrowse link
G Pla2g2a phospholipase A2 group IIA increases expression
multiple interactions
ISO belinostat results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
JBrowse link
G Pla2g4a phospholipase A2 group IVA increases expression
multiple interactions
ISO belinostat results in increased expression of PLA2G4A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
JBrowse link
G Plaat3 phospholipase A and acyltransferase 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA CTD PMID:27188386 NCBI chr 1:204,782,608...204,816,397
Ensembl chr 1:204,782,729...204,817,667
JBrowse link
G Plau plasminogen activator, urokinase increases expression
multiple interactions
ISO belinostat results in increased expression of PLAU mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
JBrowse link
G Plce1 phospholipase C, epsilon 1 decreases expression ISO belinostat results in decreased expression of PLCE1 mRNA CTD PMID:27188386 NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
JBrowse link
G Pld5 phospholipase D family, member 5 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PLD5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868
JBrowse link
G Plekha2 pleckstrin homology domain containing A2 decreases expression ISO belinostat results in decreased expression of PLEKHA2 mRNA CTD PMID:27188386 NCBI chr16:66,938,684...67,000,661 JBrowse link
G Plg plasminogen decreases expression ISO belinostat results in decreased expression of PLG mRNA CTD PMID:27188386 NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
JBrowse link
G Plpp5 phospholipid phosphatase 5 decreases expression ISO belinostat results in decreased expression of PLPP5 mRNA CTD PMID:27188386 NCBI chr16:66,349,483...66,353,887
Ensembl chr16:66,349,502...66,464,797
JBrowse link
G Plxnc1 plexin C1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PLXNC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
JBrowse link
G Pnliprp2 pancreatic lipase related protein 2 decreases expression ISO belinostat results in decreased expression of PNLIPRP2 mRNA CTD PMID:27188386 NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
JBrowse link
G Pnma2 PNMA family member 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PNMA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:41,111,942...41,119,649
Ensembl chr15:41,112,009...41,121,427
JBrowse link
G Podxl podocalyxin-like increases expression
multiple interactions
ISO belinostat results in increased expression of PODXL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
JBrowse link
G Polr3g RNA polymerase III subunit G increases expression
multiple interactions
ISO belinostat results in increased expression of POLR3G mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:11,945,217...11,986,125
JBrowse link
G Pou2f3 POU class 2 homeobox 3 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA
belinostat results in increased expression of POU2F3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:43,495,408...43,577,795
Ensembl chr 8:43,495,527...43,577,795
JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO belinostat results in increased expression of POU5F1 mRNA CTD PMID:26272509 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
JBrowse link
G Pou6f2 POU class 6 homeobox 2 increases expression ISO belinostat results in increased expression of POU6F2 mRNA CTD PMID:27188386 NCBI chr17:46,471,819...46,922,406 JBrowse link
G Ppargc1b PPARG coactivator 1 beta increases expression
multiple interactions
ISO belinostat results in increased expression of PPARGC1B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
JBrowse link
G Ppic peptidylprolyl isomerase C increases expression
multiple interactions
ISO belinostat results in increased expression of PPIC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:46,842,410...46,855,016
Ensembl chr18:46,842,409...46,855,017
JBrowse link
G Ppm1k protein phosphatase, Mg2+/Mn2+ dependent, 1K increases expression
multiple interactions
ISO belinostat results in increased expression of PPM1K mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:87,612,204...87,636,152
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO belinostat results in increased expression of PPP1R15A mRNA CTD PMID:29733868 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Ppp1r3b protein phosphatase 1, regulatory subunit 3B increases expression
multiple interactions
ISO belinostat results in increased expression of PPP1R3B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406
JBrowse link
G Ppp4r4 protein phosphatase 4, regulatory subunit 4 increases expression ISO belinostat results in increased expression of PPP4R4 mRNA CTD PMID:27188386 NCBI chr 6:122,663,172...122,753,988
Ensembl chr 6:122,663,344...122,753,384
JBrowse link
G Prdm14 PR/SET domain 14 increases expression
multiple interactions
ISO belinostat results in increased expression of PRDM14 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:6,082,163...6,092,712
Ensembl chr 5:6,082,442...6,092,712
JBrowse link
G Prima1 proline rich membrane anchor 1 decreases expression ISO belinostat results in decreased expression of PRIMA1 mRNA CTD PMID:27188386 NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of PRKACA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
JBrowse link
G Prr15 proline rich 15 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA CTD PMID:27188386 NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
JBrowse link
G Prss23 serine protease 23 decreases expression
multiple interactions
ISO belinostat results in decreased expression of PRSS23 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
JBrowse link
G Pstk phosphoseryl-tRNA kinase decreases expression ISO belinostat results in decreased expression of PSTK mRNA CTD PMID:27188386 NCBI chr 1:186,157,730...186,168,145
Ensembl chr 1:186,157,707...186,168,145
JBrowse link
G Ptp4a3 protein tyrosine phosphatase 4A3 decreases expression ISO belinostat results in decreased expression of PTP4A3 mRNA CTD PMID:27188386 NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919
JBrowse link
G Ptpn3 protein tyrosine phosphatase, non-receptor type 3 decreases expression ISO belinostat results in decreased expression of PTPN3 mRNA CTD PMID:27188386 NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443
JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 decreases expression ISO belinostat results in decreased expression of PTPN5 mRNA CTD PMID:27188386 NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
JBrowse link
G Ptx3 pentraxin 3 decreases expression ISO belinostat results in decreased expression of PTX3 mRNA CTD PMID:26272509 NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
JBrowse link
G Pyroxd2 pyridine nucleotide-disulphide oxidoreductase domain 2 decreases expression ISO belinostat results in decreased expression of PYROXD2 mRNA CTD PMID:27188386 NCBI chr 1:241,523,278...241,549,083
Ensembl chr 1:241,523,377...241,548,761
JBrowse link
G Rab29 RAB29, member RAS oncogene family increases expression ISO belinostat results in increased expression of RAB29 mRNA CTD PMID:27188386 NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417
JBrowse link
G Rab33a RAB33A, member RAS oncogene family multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA CTD PMID:27188386 NCBI chr  X:127,694,219...127,706,378
Ensembl chr  X:127,694,964...127,706,378
JBrowse link
G Rab3c RAB3C, member RAS oncogene family increases expression
multiple interactions
ISO belinostat results in increased expression of RAB3C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:41,627,720...41,843,749
JBrowse link
G Rab3ip RAB3A interacting protein multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA CTD PMID:27188386 NCBI chr 7:52,531,461...52,575,295
Ensembl chr 7:52,532,401...52,561,043
JBrowse link
G Rabgap1l RAB GTPase activating protein 1-like increases expression
multiple interactions
ISO belinostat results in increased expression of RABGAP1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984
JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression ISO belinostat results in decreased expression of RAC1 mRNA CTD PMID:19606018 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
JBrowse link
G Rad17 RAD17 checkpoint clamp loader component decreases expression ISO belinostat results in decreased expression of RAD17 mRNA CTD PMID:29733868 NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072
JBrowse link
G Rad18 RAD18 E3 ubiquitin protein ligase decreases expression ISO belinostat results in decreased expression of RAD18 mRNA CTD PMID:29733868 NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
JBrowse link
G Rad51c RAD51 paralog C decreases expression ISO belinostat results in decreased expression of RAD51C mRNA; belinostat results in decreased expression of RAD51C protein CTD PMID:29733868 NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248
JBrowse link
G Rad9a RAD9 checkpoint clamp component A decreases expression ISO belinostat results in decreased expression of RAD9A mRNA CTD PMID:29733868 NCBI chr 1:201,488,511...201,553,582
Ensembl chr 1:201,487,136...201,553,608
JBrowse link
G Ran RAN, member RAS oncogene family decreases expression ISO belinostat results in decreased expression of RAN mRNA CTD PMID:19606018 NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
JBrowse link
G Rarres1 retinoic acid receptor responder 1 decreases expression ISO belinostat results in decreased expression of RARRES1 mRNA CTD PMID:27188386 NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978
JBrowse link
G Rarres2 retinoic acid receptor responder 2 increases expression
multiple interactions
ISO belinostat results in increased expression of RARRES2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
JBrowse link
G Rasef RAS and EF hand domain containing increases expression ISO belinostat results in increased expression of RASEF mRNA CTD PMID:26272509 NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031
JBrowse link
G Rax retina and anterior neural fold homeobox decreases expression
multiple interactions
ISO belinostat results in decreased expression of RAX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:59,463,737...59,467,431
Ensembl chr18:59,463,737...59,467,431
JBrowse link
G Rbfox3 RNA binding fox-1 homolog 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of RBFOX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935
JBrowse link
G Rcbtb2 RCC1 and BTB domain containing protein 2 decreases expression ISO belinostat results in decreased expression of RCBTB2 mRNA CTD PMID:27188386 NCBI chr15:48,319,809...48,364,441
Ensembl chr15:48,323,866...48,383,750
JBrowse link
G Rcc2 regulator of chromosome condensation 2 decreases expression ISO belinostat results in decreased expression of RCC2 mRNA CTD PMID:19606018 NCBI chr 5:152,994,406...153,017,223
Ensembl chr 5:152,993,665...153,017,205
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases acetylation
ISO Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein] CTD PMID:18223231 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Reln reelin increases expression ISO belinostat results in increased expression of RELN mRNA CTD PMID:26272509 NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
JBrowse link
G Rev1 REV1, DNA directed polymerase decreases expression ISO belinostat results in decreased expression of REV1 mRNA CTD PMID:29733868 NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576
JBrowse link
G RGD1359508 similar to protein C33A12.3 increases expression ISO belinostat results in increased expression of C4ORF33 mRNA CTD PMID:27188386 NCBI chr 2:124,764,263...124,830,001
Ensembl chr 2:124,769,940...124,832,449
JBrowse link
G RGD1564053 similar to hypothetical protein multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA
belinostat results in increased expression of C8ORF34 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:7,238,853...7,776,769
JBrowse link
G RGD1564664 similar to LOC387763 protein increases expression
multiple interactions
ISO belinostat results in increased expression of C11ORF96 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:79,920,131...79,921,523
Ensembl chr 3:79,920,129...79,921,523
JBrowse link
G Rhob ras homolog family member B increases expression
multiple interactions
ISO belinostat results in increased expression of RHOB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
JBrowse link
G Rnf144b ring finger protein 144B increases expression
multiple interactions
ISO belinostat results in increased expression of RNF144B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:17,431,271...17,580,687
Ensembl chr17:17,432,786...17,562,760
JBrowse link
G Rnf150 ring finger protein 150 increases expression
multiple interactions
ISO belinostat results in increased expression of RNF150 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:25,006,978...25,229,273
Ensembl chr19:25,006,611...25,228,678
JBrowse link
G Rnf180 ring finger protein 180 decreases expression ISO belinostat results in decreased expression of RNF180 mRNA CTD PMID:27188386 NCBI chr 2:36,330,285...36,511,168
Ensembl chr 2:36,330,292...36,512,614
JBrowse link
G Rnf217 ring finger protein 217 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA
belinostat results in increased expression of RNF217 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:26,015,728...26,108,736
JBrowse link
G Robo2 roundabout guidance receptor 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of ROBO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
JBrowse link
G Rph3al rabphilin 3A-like (without C2 domains) multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA CTD PMID:27188386 NCBI chr10:60,689,943...60,833,354
Ensembl chr10:60,690,031...60,801,883
JBrowse link
G Rsl1d1 ribosomal L1 domain containing 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA CTD PMID:27188386 NCBI chr10:4,424,868...4,436,753
Ensembl chr10:4,397,821...4,439,593
JBrowse link
G RT1-DMb RT1 class II, locus DMb decreases expression
multiple interactions
ISO belinostat results in decreased expression of HLA-DMB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
JBrowse link
G RT1-Ha RT1 class II, locus Ha decreases expression ISO belinostat results in decreased expression of HLA-DPA1 mRNA CTD PMID:27188386 NCBI chr20:4,760,631...4,770,662 JBrowse link
G Rtn1 reticulon 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA
belinostat results in decreased expression of RTN1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
JBrowse link
G Rtp1 receptor (chemosensory) transporter protein 1 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA CTD PMID:27188386 NCBI chr11:77,422,982...77,425,498
Ensembl chr11:77,422,982...77,425,498
JBrowse link
G Runx1t1 RUNX1 partner transcriptional co-repressor 1 increases expression
multiple interactions
ISO belinostat results in increased expression of RUNX1T1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592
JBrowse link
G S100a10 S100 calcium binding protein A10 increases expression
multiple interactions
ISO belinostat results in increased expression of S100A10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
JBrowse link
G S1pr3 sphingosine-1-phosphate receptor 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of S1PR3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
JBrowse link
G Sat1 spermidine/spermine N1-acetyl transferase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA
belinostat results in increased expression of SAT1 mRNA
CTD PMID:19606018 PMID:26272509 PMID:27188386 NCBI chr  X:40,158,354...40,161,641
Ensembl chr  X:40,157,046...40,196,813
JBrowse link
G Scg3 secretogranin III increases expression
multiple interactions
ISO belinostat results in increased expression of SCG3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
JBrowse link
G Scgb3a2 secretoglobin, family 3A, member 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA
belinostat results in increased expression of SCGB3A2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr18:35,932,840...35,935,762
Ensembl chr18:35,932,840...35,935,762
JBrowse link
G Sclt1 sodium channel and clathrin linker 1 increases expression ISO belinostat results in increased expression of SCLT1 mRNA CTD PMID:27188386 NCBI chr 2:124,605,445...124,763,964
Ensembl chr 2:124,605,658...124,764,065
JBrowse link
G Scml1 Scm polycomb group protein like 1 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA
belinostat results in increased expression of SCML1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:32,893,100...32,912,686 JBrowse link
G Scnn1a sodium channel epithelial 1 subunit alpha increases expression
multiple interactions
ISO belinostat results in increased expression of SCNN1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181
JBrowse link
G Sdsl serine dehydratase-like decreases expression
multiple interactions
ISO belinostat results in decreased expression of SDSL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr12:36,099,693...36,109,914
Ensembl chr12:36,099,693...36,109,906
JBrowse link
G Sema3b semaphorin 3B decreases expression ISO belinostat results in decreased expression of SEMA3B mRNA CTD PMID:27188386 NCBI chr 8:108,271,663...108,280,326
Ensembl chr 8:108,271,666...108,282,919
JBrowse link
G Sema3c semaphorin 3C increases expression ISO belinostat results in increased expression of SEMA3C mRNA CTD PMID:26272509 NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534
JBrowse link
G Sema3e semaphorin 3E increases expression
multiple interactions
ISO belinostat results in increased expression of SEMA3E mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:20,297,534...20,555,287
Ensembl chr 4:20,299,718...20,555,229
JBrowse link
G Sema3f semaphorin 3F decreases expression ISO belinostat results in decreased expression of SEMA3F mRNA CTD PMID:27188386 NCBI chr 8:108,357,629...108,387,083
Ensembl chr 8:108,357,629...108,387,083
JBrowse link
G Sema6d semaphorin 6D decreases expression ISO belinostat results in decreased expression of SEMA6D mRNA CTD PMID:26272509 NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094
JBrowse link
G Septin6 septin 6 increases expression
multiple interactions
ISO belinostat results in increased expression of SEPTIN6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr  X:116,153,255...116,230,334
Ensembl chr  X:116,153,255...116,230,115
JBrowse link
G Serpina1 serpin family A member 1 decreases expression ISO belinostat results in decreased expression of SERPINA1 mRNA CTD PMID:27188386 NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
JBrowse link
G Serpina7 serpin family A member 7 decreases expression ISO belinostat results in decreased expression of SERPINA7 mRNA CTD PMID:27188386 NCBI chr  X:102,663,242...102,722,319
Ensembl chr  X:102,663,405...102,669,040
JBrowse link
G Serpinb1a serpin family B member 1A decreases expression ISO belinostat results in decreased expression of SERPINB1 mRNA CTD PMID:27188386 NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
JBrowse link
G Serpinb9 serpin family B member 9 increases expression
multiple interactions
ISO belinostat results in increased expression of SERPINB9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
JBrowse link
G Serpini1 serpin family I member 1 increases expression
multiple interactions
ISO belinostat results in increased expression of SERPINI1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135
JBrowse link
G Sesn3 sestrin 3 increases expression ISO belinostat results in increased expression of SESN3 mRNA CTD PMID:26272509 NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842
JBrowse link
G Sez6 seizure related 6 homolog increases expression
multiple interactions
ISO belinostat results in increased expression of SEZ6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:62,818,931...62,868,686
Ensembl chr10:62,819,069...62,868,671
JBrowse link
G Sfmbt2 Scm-like with four mbt domains 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SFMBT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:67,934,296...68,128,905
Ensembl chr17:67,935,904...68,128,781
JBrowse link
G Sgk3 serum/glucocorticoid regulated kinase family, member 3 increases expression
multiple interactions
ISO belinostat results in increased expression of SGK3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476
JBrowse link
G Shc3 SHC adaptor protein 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA CTD PMID:27188386 NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,651,202...13,772,710
JBrowse link
G Shisal1 shisa like 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA
belinostat results in decreased expression of SHISAL1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:115,506,947...115,611,518
Ensembl chr 7:115,509,035...115,575,449
JBrowse link
G Shroom1 shroom family member 1 decreases expression ISO belinostat results in decreased expression of SHROOM1 mRNA CTD PMID:27188386 NCBI chr10:37,621,149...37,631,895
Ensembl chr10:37,621,723...37,631,256
JBrowse link
G Siae sialic acid acetylesterase increases expression ISO belinostat results in increased expression of SIAE mRNA CTD PMID:27188386 NCBI chr 8:37,318,724...37,354,004
Ensembl chr 8:37,318,747...37,353,996
JBrowse link
G Six3 SIX homeobox 3 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SIX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:9,040,123...9,043,336
Ensembl chr 6:9,036,434...9,053,301
JBrowse link
G Six6os1 Six6 opposite strand transcript 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA
belinostat results in decreased expression of C14ORF39 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:91,579,185...91,615,183
Ensembl chr 6:91,579,325...91,615,148
JBrowse link
G Skap2 src kinase associated phosphoprotein 2 increases expression ISO belinostat results in increased expression of SKAP2 mRNA CTD PMID:27188386 NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
JBrowse link
G Slc16a14 solute carrier family 16, member 14 multiple interactions
decreases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA
belinostat results in decreased expression of SLC16A14 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:86,112,894...86,137,318
JBrowse link
G Slc1a3 solute carrier family 1 member 3 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA CTD PMID:27188386 NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
JBrowse link
G Slc25a21 solute carrier family 25 member 21 decreases expression ISO belinostat results in decreased expression of SLC25A21 mRNA CTD PMID:27188386 NCBI chr 6:74,203,439...74,702,902
Ensembl chr 6:74,203,440...74,702,680
JBrowse link
G Slc27a2 solute carrier family 27 member 2 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA CTD PMID:27188386 NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
JBrowse link
G Slc35d3 solute carrier family 35, member D3 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC35D3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:14,565,482...14,573,581
Ensembl chr 1:14,569,687...14,573,159
JBrowse link
G Slc35f3 solute carrier family 35, member F3 decreases expression ISO belinostat results in decreased expression of SLC35F3 mRNA CTD PMID:27188386 NCBI chr19:54,102,811...54,371,765
Ensembl chr19:54,103,120...54,372,839
JBrowse link
G Slc38a4 solute carrier family 38, member 4 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC38A4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
JBrowse link
G Slc38a6 solute carrier family 38, member 6 increases expression
multiple interactions
ISO belinostat results in increased expression of SLC38A6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935
JBrowse link
G Slc43a1 solute carrier family 43 member 1 increases expression ISO belinostat results in increased expression of SLC43A1 mRNA CTD PMID:26272509 NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:69,920,649...69,946,768
JBrowse link
G Slc44a3 solute carrier family 44, member 3 decreases expression ISO belinostat results in decreased expression of SLC44A3 mRNA CTD PMID:27188386 NCBI chr 2:209,552,138...209,628,182
Ensembl chr 2:209,552,144...209,629,044
JBrowse link
G Slc6a2 solute carrier family 6 member 2 increases expression ISO belinostat results in increased expression of SLC6A2 mRNA CTD PMID:27188386 NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO belinostat results in decreased expression of SLC7A11 mRNA CTD PMID:27188386 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
JBrowse link
G Slc9b2 solute carrier family 9 member B2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SLC9B2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225
JBrowse link
G Slco4c1 solute carrier organic anion transporter family, member 4C1 increases expression
multiple interactions
ISO belinostat results in increased expression of SLCO4C1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:97,180,162...97,229,135
Ensembl chr 9:97,178,861...97,229,715
JBrowse link
G Slfn4 schlafen family member 4 increases expression ISO belinostat results in increased expression of SLFN12 mRNA CTD PMID:27188386 NCBI chr10:67,994,601...68,018,141
Ensembl chr10:68,000,028...68,018,138
Ensembl chr10:68,000,028...68,018,138
JBrowse link
G Slit1 slit guidance ligand 1 increases expression
multiple interactions
ISO belinostat results in increased expression of SLIT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
JBrowse link
G Slit2 slit guidance ligand 2 increases expression ISO belinostat results in increased expression of SLIT2 mRNA CTD PMID:26272509 NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948
JBrowse link
G Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SMARCA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:224,191,125...224,358,640
Ensembl chr 1:224,191,125...224,358,684
JBrowse link
G Smoc1 SPARC related modular calcium binding 1 decreases expression
multiple interactions
ISO belinostat results in decreased expression of SMOC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:100,701,330...100,897,441
Ensembl chr 6:100,701,346...100,862,699
JBrowse link
G Snai2 snail family transcriptional repressor 2 increases expression
multiple interactions
ISO belinostat results in increased expression of SNAI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200
JBrowse link
G Snap25 synaptosome associated protein 25 increases expression
multiple interactions
ISO belinostat results in increased expression of SNAP25 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
JBrowse link
G Snx10 sorting nexin 10 decreases expression ISO belinostat results in decreased expression of SNX10 mRNA CTD PMID:27188386 NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
JBrowse link
G Socs3 suppressor of cytokine signaling 3 decreases expression ISO belinostat results in decreased expression of SOCS3 mRNA CTD PMID:26272509 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
JBrowse link
G Sox6 SRY-box transcription factor 6 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA CTD PMID:27188386 NCBI chr 1:169,723,306...170,334,846
Ensembl chr 1:169,729,194...170,277,386
JBrowse link
G Sox8 SRY-box transcription factor 8 increases expression
multiple interactions
ISO belinostat results in increased expression of SOX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
JBrowse link
G Spink2 serine peptidase inhibitor, Kazal type 2 increases expression ISO belinostat results in increased expression of SPINK2 mRNA CTD PMID:26272509 NCBI chr14:30,967,682...30,974,326
Ensembl chr14:30,967,714...30,974,326
JBrowse link
G Spx spexin hormone decreases expression ISO belinostat results in decreased expression of SPX mRNA CTD PMID:27188386 NCBI chr 4:175,356,044...175,362,082
Ensembl chr 4:175,356,247...175,362,082
JBrowse link
G Sspn sarcospan decreases expression ISO belinostat results in decreased expression of SSPN mRNA CTD PMID:27188386 NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
JBrowse link
G Sst somatostatin increases expression ISO belinostat results in increased expression of SST mRNA CTD PMID:26272509 NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
JBrowse link
G Stc2 stanniocalcin 2 decreases expression ISO belinostat results in decreased expression of STC2 mRNA CTD PMID:27188386 NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
JBrowse link
G Stk32a serine/threonine kinase 32A decreases expression ISO belinostat results in decreased expression of STK32A mRNA CTD PMID:27188386 NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,259,052...35,369,451
JBrowse link
G Stmn2 stathmin 2 increases expression
multiple interactions
ISO belinostat results in increased expression of STMN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:93,204,692...93,252,011
JBrowse link
G Sult1c2a sulfotransferase family, cytosolic, 1C, member 2a increases expression
decreases expression
multiple interactions
ISO belinostat results in increased expression of SULT1C2 mRNA
belinostat results in decreased expression of SULT1C2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 decreases expression ISO belinostat results in decreased expression of SULT2A1 mRNA CTD PMID:27188386 NCBI chr 1:75,451,178...75,508,142 JBrowse link
G Susd1 sushi domain containing 1 decreases expression ISO belinostat results in decreased expression of SUSD1 mRNA CTD PMID:27188386 NCBI chr 5:74,157,653...74,281,171
Ensembl chr 5:74,157,773...74,276,291
JBrowse link
G Synj2 synaptojanin 2 decreases expression ISO belinostat results in decreased expression of SYNJ2 mRNA CTD PMID:26272509 NCBI chr 1:46,518,594...46,621,919
Ensembl chr 1:46,518,709...46,633,687
JBrowse link
G Synm synemin decreases expression ISO belinostat results in decreased expression of SYNM mRNA CTD PMID:27188386 NCBI chr 1:121,333,712...121,363,652
Ensembl chr 1:121,333,720...121,363,652
JBrowse link
G Tacc1 transforming, acidic coiled-coil containing protein 1 increases expression ISO belinostat results in increased expression of TACC1 mRNA CTD PMID:19606018 NCBI chr16:66,812,232...66,895,736
Ensembl chr16:66,812,295...66,895,733
JBrowse link
G Tacstd2 tumor-associated calcium signal transducer 2 multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
belinostat results in increased expression of TACSTD2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 4:96,707,950...96,709,650
Ensembl chr 4:96,707,951...96,709,650
JBrowse link
G Tafa2 TAFA chemokine like family member 2 increases expression
multiple interactions
ISO belinostat results in increased expression of TAFA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 7:58,942,598...59,418,640 JBrowse link
G Taok3 TAO kinase 3 increases expression ISO belinostat results in increased expression of TAOK3 mRNA CTD PMID:26272509 NCBI chr12:39,314,027...39,394,243
Ensembl chr12:39,314,027...39,461,244
JBrowse link
G Tc2n tandem C2 domains, nuclear increases expression
multiple interactions
ISO belinostat results in increased expression of TC2N mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:120,761,119...120,849,326
JBrowse link
G Tcaim T cell activation inhibitor, mitochondrial decreases expression ISO belinostat results in decreased expression of TCAIM mRNA CTD PMID:27188386 NCBI chr 8:122,414,827...122,446,105
Ensembl chr 8:122,414,818...122,446,092
JBrowse link
G Tdgf1 teratocarcinoma-derived growth factor 1 increases expression ISO belinostat results in increased expression of TDGF1 mRNA CTD PMID:26272509 NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308
JBrowse link
G Tfap2a transcription factor AP-2 alpha increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507
JBrowse link
G Tfap2b transcription factor AP-2 beta increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 9:21,786,250...21,815,785
Ensembl chr 9:21,786,258...21,814,520
JBrowse link
G Tfap2c transcription factor AP-2 gamma increases expression
multiple interactions
ISO belinostat results in increased expression of TFAP2C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995
JBrowse link
G Tff1 trefoil factor 1 decreases expression ISO belinostat results in decreased expression of TFF1 mRNA CTD PMID:27188386 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tff2 trefoil factor 2 decreases expression ISO belinostat results in decreased expression of TFF2 mRNA CTD PMID:27188386 NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
JBrowse link
G Tfpi tissue factor pathway inhibitor increases expression
multiple interactions
ISO belinostat results in increased expression of TFPI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
JBrowse link
G Tgfb2 transforming growth factor, beta 2 increases expression ISO belinostat results in increased expression of TGFB2 mRNA CTD PMID:23671600 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
JBrowse link
G Thrb thyroid hormone receptor beta increases expression
multiple interactions
ISO belinostat results in increased expression of THRB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO belinostat results in decreased expression of TIMP3 mRNA CTD PMID:26272509 NCBI chr 7:17,520,827...17,571,871
Ensembl chr 7:17,521,919...17,571,839
JBrowse link
G Tmem220 transmembrane protein 220 decreases expression ISO belinostat results in decreased expression of TMEM220 mRNA CTD PMID:27188386 NCBI chr10:51,719,777...51,728,792
Ensembl chr10:51,719,777...51,728,776
JBrowse link
G Tmem221 transmembrane protein 221 decreases expression ISO belinostat results in decreased expression of TMEM221 mRNA CTD PMID:26272509 NCBI chr16:18,253,622...18,271,094
Ensembl chr16:18,262,052...18,266,967
JBrowse link
G Tmem30b transmembrane protein 30B multiple interactions
increases expression
ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA
belinostat results in increased expression of TMEM30B mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 6:92,251,626...92,254,702
Ensembl chr 6:92,249,790...92,254,842
JBrowse link
G Tmem44 transmembrane protein 44 decreases expression ISO belinostat results in decreased expression of TMEM44 mRNA CTD PMID:27188386 NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958
JBrowse link
G Tmem51 transmembrane protein 51 decreases expression ISO belinostat results in decreased expression of TMEM51 mRNA CTD PMID:27188386 NCBI chr 5:154,325,853...154,375,882
Ensembl chr 5:154,325,856...154,375,882
JBrowse link
G Tmem64 transmembrane protein 64 increases expression
multiple interactions
ISO belinostat results in increased expression of TMEM64 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:28,698,918...28,745,330
JBrowse link
G Tnc tenascin C decreases expression
multiple interactions
ISO belinostat results in decreased expression of TNC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA CTD PMID:27188386 NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
JBrowse link
G Tnik TRAF2 and NCK interacting kinase increases expression
multiple interactions
ISO belinostat results in increased expression of TNIK mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750
JBrowse link
G Tnn tenascin N multiple interactions ISO [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA CTD PMID:27188386 NCBI chr13:72,319,160...72,386,362
Ensembl chr13:72,319,155...72,408,156
JBrowse link
G Tox2 TOX high mobility group box family member 2 decreases expression
multiple interactions
ISO belinostat results in decreased expression of TOX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:151,853,294...151,980,749
JBrowse link
G Tp53 tumor protein p53 decreases expression ISO belinostat results in decreased expression of TP53 mRNA
belinostat results in decreased expression of TRP53 mRNA; belinostat results in decreased expression of TRP53 protein
CTD PMID:19606018 PMID:29733868 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Tpd52l1 TPD52 like 1 increases expression
multiple interactions
ISO belinostat results in increased expression of TPD52L1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109
JBrowse link
G Tpx2 TPX2, microtubule nucleation factor decreases expression ISO belinostat results in decreased expression of TPX2 mRNA CTD PMID:19606018 NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
JBrowse link
G Trib3 tribbles pseudokinase 3 decreases expression ISO belinostat results in decreased expression of TRIB3 mRNA CTD PMID:27188386 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
JBrowse link
G Trnp1 TMF1-regulated nuclear protein 1 increases expression
multiple interactions
ISO belinostat results in increased expression of TRNP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr 5:145,706,427...145,713,279
Ensembl chr 5:145,706,094...145,713,272
JBrowse link
G Ttc29 tetratricopeptide repeat domain 29 increases expression
multiple interactions
ISO belinostat results in increased expression of TTC29 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA
CTD PMID:26272509 PMID:27188386 NCBI chr19:29,531,707...29,750,635
Ensembl chr19:29,532,663...29,750,615
JBrowse link
G Tuba1a tubulin, alpha 1A affects expression ISO belinostat affects the expression of TUBA1A mRNA CTD PMID:27015953 NCBI chr 7:130,113,214...130,116,880 JBrowse link
G Tuft1 tuftelin 1 increases expression ISO belinostat results in increased expression of TUFT1 mRNA CTD PMID:19606018 NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192
JBrowse link
G Twist1 twist family bHLH transcription factor 1 increases expression ISO belinostat results in increased expression of TWIST1 protein CTD PMID:23671600 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
JBrowse link
G Txnrd3 thioredoxin reductase 3 decreases expression ISO belinostat results in decreased expression of TXNRD3 mRNA CTD PMID:27188386 NCBI chr 4:122,072,548...122,112,493
Ensembl chr 4:122,072,548...122,112,491
JBrowse link
G Tyms thymidylate synthetase decreases expression ISO belinostat results in decreased expression of TYMS mRNA CTD PMID:19606018 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 decreases glucuronidation
multiple interactions
increases glucuronidation
ISO UGT1A1 gene polymorphism results in decreased glucuronidation of belinostat
belinostat inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]
UGT1A1 protein results in increased glucuronidation of belinostat
CTD PMID:23382909 PMID:33290829 NCBI chr 9:88,801,344...88,808,465 JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 multiple interactions ISO belinostat inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone] CTD PMID:33290829 NCBI chr 9:88,791,216...88,808,465 JBrowse link